# A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus

> **NCT00630825** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 262 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** LY2189265
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00630825
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 262 (ACTUAL)
- **Last updated:** 2014-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00630825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00630825, "A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00630825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*